Immunic (NASDAQ:IMUX) Given New $8.00 Price Target at HC Wainwright

Immunic (NASDAQ:IMUX) had its target price trimmed by HC Wainwright from $10.00 to $8.00 in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently commented on IMUX. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, October 8th. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. D. Boral Capital lowered their price target on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday. Chardan Capital initiated coverage on Immunic in a research note on Monday, September 29th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, Roth Capital initiated coverage on shares of Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Immunic Trading Up 9.3%

Shares of NASDAQ:IMUX traded up $0.07 on Friday, hitting $0.78. The company had a trading volume of 1,257,137 shares, compared to its average volume of 1,289,562. The company has a market cap of $76.80 million, a PE ratio of -0.83 and a beta of 1.53. The business has a 50 day moving average of $0.83 and a 200 day moving average of $0.86. Immunic has a 52-week low of $0.56 and a 52-week high of $1.42.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. As a group, equities analysts predict that Immunic will post -0.94 EPS for the current year.

Institutional Trading of Immunic

Several institutional investors have recently added to or reduced their stakes in IMUX. Two Sigma Investments LP acquired a new position in shares of Immunic in the 3rd quarter valued at about $52,000. HB Wealth Management LLC bought a new stake in shares of Immunic in the 3rd quarter worth approximately $81,000. Virtu Financial LLC acquired a new position in Immunic during the 3rd quarter valued at approximately $99,000. GSA Capital Partners LLP bought a new position in Immunic during the 3rd quarter worth $170,000. Finally, Jane Street Group LLC lifted its stake in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.